FARSB Facilitates Hepatocellular Carcinoma Progression by Activating the mTORC1 Signaling Pathway

被引：6

作者：

Wang, Yaofeng ^{[1
]}

Wang, Gengqiao ^{[1
]}

Hu, Shaobo ^{[1
]}

Yin, Chuanzheng ^{[1
]}

Zhao, Peng ^{[1
]}

Zhou, Xing ^{[1
]}

Shao, Shuyu ^{[1
]}

Liu, Ran ^{[1
]}

Hu, Wenjun ^{[2
]}

Liu, Gang Logan ^{[2
]}

Ke, Wenbo ^{[1
]}

Song, Zifang ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan 430022, Peoples R China

[2] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Wuhan 430074, Peoples R China

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 23期

基金：

中国国家自然科学基金;

关键词：

FARSB; hepatocellular carcinoma; mTORC1; Raptor; ferroptosis; TRANSFER-RNA SYNTHETASE; FERROPTOSIS;

D O I：

10.3390/ijms242316709

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Hepatocellular carcinoma (HCC) is a common malignant tumor with high mortality. Human phenylalanine tRNA synthetase (PheRS) comprises two alpha catalytic subunits encoded by the FARSA gene and two beta regulatory subunits encoded by the FARSB gene. FARSB is a potential oncogene, but no experimental data show the relationship between FARSB and HCC progression. We found that the high expression of FARSB in liver cancer is closely related to patients' low survival and poor prognosis. In liver cancer cells, the mRNA and protein expression levels of FARSB are increased and promote cell proliferation and migration. Mechanistically, FARSB activates the mTOR complex 1 (mTORC1) signaling pathway by binding to the component Raptor of the mTORC1 complex to play a role in promoting cancer. In addition, we found that FARSB can inhibit erastin-induced ferroptosis by regulating the mTOR signaling pathway, which may be another mechanism by which FARSB promotes HCC progression. In summary, FARSB promotes HCC progression and is associated with the poor prognosis of patients. FARSB is expected to be a biomarker for early screening and treatment of HCC.

引用

页数：17

共 34 条

[1] Recent progress in the immunotherapy of hepatocellular carcinoma: Non-coding RNA-based immunotherapy may improve the outcome [J].